Core Insights - The "14th Five-Year Plan" period is identified as a golden opportunity for Weigao Blood Purification to achieve leapfrog development, with significant advancements in domestic substitution, full industry chain construction, and key capital market positioning [2] - Weigao Blood Purification successfully listed on the Shanghai Stock Exchange in May 2025, raising a net amount of 978 million yuan, marking it as one of the largest IPOs in the medical device sector this year [2] - The company has established a comprehensive product line in the blood purification field, covering dialysis devices, machines, and peritoneal dialysis solutions, creating a competitive advantage through technological synergy and scale effects [2] Industry and Market Position - Weigao Blood Purification has leveraged national policies to expand its market share, with a focus on high-quality development and accelerated domestic substitution in the medical device industry [2][3] - The company has built production bases in various locations, including Weihai, Chengdu, and Jiangxi, forming a nationwide capacity network supported by medical device industry cluster policies [3] - The company has committed to a cash dividend policy post-IPO, distributing a total of 65.82 million yuan in cash dividends, with the mid-2025 dividend accounting for 29.89% of the net profit during the same period [3] Future Strategy - Weigao Blood Purification aims to focus on "innovation-driven, global layout, and industry chain extension" as its strategic directions, increasing R&D investment to drive core technology breakthroughs and product upgrades [3] - The company plans to deepen its market presence in Southeast Asia, South America, Eastern Europe, and North Africa, enhancing its overseas market penetration [3] - Weigao Blood Purification will pursue mergers and acquisitions to expand its business boundaries and capitalize on domestic substitution opportunities through both organic and external growth strategies [3]

Group 1 - The core point of the announcement is that Shandong Weigao Blood Purification Products Co., Ltd. has approved a capital increase in its joint venture, Weigao Taiermao (Weihai) Medical Products Co., Ltd., to support the development of peritoneal dialysis fluid business [3][9][14] - The board meeting was held on November 20, 2025, with all nine directors present, and the decision-making process complied with relevant laws and regulations [2][5][16] - The company plans to invest 72.5 million RMB in the joint venture, increasing its registered capital from 160 million RMB to 305 million RMB, while maintaining a 50% ownership stake [8][9][14] Group 2 - The capital increase is part of the company's strategic planning and aims to meet the needs of its peritoneal dialysis fluid business [8][14] - The transaction does not constitute a major asset restructuring and has been approved by the independent directors and the board of directors [9][15][17] - The joint venture's ownership structure remains unchanged, with both the company and Taiermao China holding 50% each [10][14]

Core Points - Weigao Blood Purification announced on November 20 that it has approved a proposal for proportional capital increase in its joint venture with Tailormade (China) Investment Co., Ltd. [1] - The company plans to increase its investment by 72.5 million RMB in Weigao Tailormade (Weihai) Medical Products Co., Ltd. [1] - This capital increase does not require approval from the company's shareholders' meeting. [1]

Group 1 - The core point of the article is that Weigao Blood Products (SH 603014) held its 18th meeting of the second board of directors on November 20, 2025, to review proposals including capital increase in joint ventures and related transactions [1] - For the first half of 2025, Weigao Blood Products reported that its revenue composition was as follows: consumables accounted for 77.55%, equipment accounted for 18.25%, other businesses accounted for 2.35%, and other categories accounted for 1.85% [1] - As of the time of reporting, Weigao Blood Products had a market capitalization of 16.8 billion yuan [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business, in collaboration with Terumo China [1] Group 1: Capital Increase Details - The company plans to increase its investment by 72.5 million RMB [1] - After the capital increase, the registered capital of Weigao Terumo will rise from 160 million RMB to 305 million RMB [1] - The company's ownership stake in Weigao Terumo will remain unchanged at 50% [1] Group 2: Joint Venture Structure - Weigao Terumo will continue to be a jointly controlled entity between the company and Terumo China [1]

Core Viewpoint - Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business, in collaboration with Terumo China [1] Group 1: Capital Increase Details - The company plans to increase its investment by 72.5 million RMB [1] - After the capital increase, the registered capital of Weigao Terumo will rise from 160 million RMB to 305 million RMB [1] - The company's ownership stake in Weigao Terumo will remain unchanged at 50% [1] Group 2: Joint Venture Structure - Weigao Terumo will continue to be a jointly controlled entity between the company and Terumo China [1]

华泰联合证券有限责任公司 关于山东威高血液净化制品股份有限公司 对合营企业同比例增资暨关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"或"保荐机构"）作为 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）首次 公开发行股票的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》等有关规定，对公司拟对合营企业同比例增资暨关联交易 事项进行了审慎核查，核查情况如下： 一、增资暨关联交易概述 （一）基本情况 结合公司战略规划，为满足腹膜透析液业务的发展需要，公司与泰尔茂（中 国）投资有限公司（以下简称"泰尔茂中国"）拟对威高泰尔茂（威海）医疗制品 有限公司（以下简称"威高泰尔茂"）进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币。本次增资完成后，威高泰尔茂的注册资本将由 1.6 亿元人民 币增加至 3.05 亿元人民币，公司对威高泰尔茂的持股比例不变，仍为 50%，威 高泰尔茂仍属于公司与泰尔茂中国共同控制的合营企业。 2025 年 11 月 20 日，公司召开第二届董事会第十八次会议审议通过了《关 于对合营企业同比例增资暨关联交易的议案》。根 ...

Group 1 - The core point of the article is that Weigao Blood Purification (603014.SH) announced a capital increase to support the development of its peritoneal dialysis fluid business [1] - The company plans to invest 72.5 million RMB in Weigao Tailmao (Weihai) Medical Products Co., Ltd. as part of this capital increase [1] - The investment is in collaboration with Tailmao (China) Investment Co., Ltd. to meet the strategic planning needs of the company [1]

证券代码：603014 证券简称：威高血净 公告编号：2025-045 山东威高血液净化制品股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 结合公司战略规划，为满足腹膜透析液业务的发展需要，山东威高血液净化 制品股份有限公司（以下简称"公司"、"本公司"或"威高血净"）与泰尔茂（中 国）投资有限公司（以下简称"泰尔茂中国"）拟对威高泰尔茂（威海）医疗制品 有限公司（以下简称"威高泰尔茂"）进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币； 本次交易已经公司 2025 年第七次独立董事专门会议、第二届董事会第十八 次会议审议通过，关联董事已回避表决，无需提交公司股东会审议； 本次交易不构成重大资产重组。 一、增资暨关联交易概述 （一）本次交易基本情况 结合公司战略规划，为满足腹膜透析液业务的发展需要，公司与泰尔茂中国拟 对威高泰尔茂进行同比例增资，其中公司拟增资金额为 0.725 亿元人民币。本次增资 完成后，威高泰尔茂的注册资本将由 1.6 亿元人民币增加至 3.05 亿元人民币，公司 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-044 山东威高血液净化制品股份有限公司 第二届董事会第十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十八次会议于 2025 年 11 月 20 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 11 月 16 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席董事 9 人，实际出席董事 9 人；公司部分高级管理 人员列席了本次会议。本次会议的召集、召开和表决程序符合《中华人民共和国公 司法》等法律、法规、部门规章、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议，并对议案进行了投票表决，通过了以下决议： （一）审议通过了《关于对合营企业同比例增资暨关联交易的议案》 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体 ...